Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides



Status:Withdrawn
Conditions:Infectious Disease, Lymphoma
Therapuetic Areas:Immunology / Infectious Diseases, Oncology
Healthy:No
Age Range:18 - Any
Updated:1/31/2018
Start Date:August 2018
End Date:December 2021

Use our guide to learn which trials are right for you!

IIS: Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides

This phase II trial studies how well low dose total skin electron beam radiation therapy and
mechlorethamine hydrochloride gel work in treating patients with mycosis fungoides. Total
skin electron beam radiation therapy uses high energy x-rays directed at the entire surface
of the body to kill cancer cells and shrink tumors. Mechlorethamine hydrochloride gel may
help patients in remission of disease, reduction in disease staging, and enhanced quality of
life. Giving total skin electron beam radiation therapy and mechlorethamine hydrochloride gel
may work better in treating patients with mycosis fungoides.

PRIMARY OBJECTIVES:

I. To assess the time to progression of patients treated with total skin electron beam
therapy (TSEBT) followed by the year-long maintenance mechlorethamine hydrochloride gel
(Valchlor) regimen.

SECONDARY OBJECTIVES:

I. To assess the response rate (complete response [CR] and partial response [PR]) of patients
treated with total skin electron beam therapy (TSEBT) followed by the year-long maintenance
Valchlor regimen.

Inclusion Criteria:

- Documentation of diagnosis as evidenced by one or more clinical features consistent
with mycosis fungoides cutaneous T-cell lymphoma

- Written informed consent obtained from subject or subject's legal representative and
ability for subject to comply with requirements of the study

- Skin biopsy specimen of representative lesion obtained at screening of study and
deemed diagnostic of mycosis fungoides by principal investigator

- Mycosis fungoides patients that have stage T2-4 N0-1 M0B0 disease

- Availability of subject to be observed for up to 18 months post-screening evaluation

- Life expectancy greater than 6 months

Exclusion Criteria:

- Pregnant or breast-feeding females

- Presence of a condition or abnormality that in the opinion of the investigator would
compromise the safety of the patient or the quality of the data

- Patients diagnosed with Sezary syndrome; Sezary syndrome is equivalent to mycosis
fungoides that develops to stage IVA/B with B2 (high blood tumor burden) involvement,
and as such requires a more aggressive treatment regimen than Valchlor or TSEBT

- Underlying medical condition including unstable cardiac disease, or other serious
illness that would impair the ability of the patient to undergo treatment

- Minimum 3 weeks since prior systematic treatment or phototherapy

- Exclusion of people that do not understand the risks, such as decisionally-impaired
individuals, prisoners, and vulnerable populations
We found this trial at
1
site
Philadelphia, Pennsylvania 19107
Phone: 215-955-8325
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials